These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Pharmacological investigations of 4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA 2370). 6. Activity on polyarthritis induced in rats by Freund's adjuvant. Lumachi B Arzneimittelforschung; 1972 Jan; 22(1):Suppl 1a:204+. PubMed ID: 5067194 [No Abstract] [Full Text] [Related]
9. Metabolic and clinical effects of 4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA 2370). Ghiringhelli F; Mazzi C; Chierichetti S Arzneimittelforschung; 1972 Jan; 22(1):Suppl 1a:268-7. PubMed ID: 5067203 [No Abstract] [Full Text] [Related]
10. Clinical and laboratory evaluation of 4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA 2370) in rheumatoid arthritis and ankylosing spondylitis. Lignière GC; Colombo B; Carrabba M; Ferrari P; Robotti E Arzneimittelforschung; 1972 Jan; 22(1):Suppl 1a:253-8. PubMed ID: 4553232 [No Abstract] [Full Text] [Related]
11. Survey of the biological properties of 4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA 2370), a novel agent in the class of anti-inflammatory drugs. Bianchi C Arzneimittelforschung; 1972 Jan; 22(1):Suppl 1a:249-5. PubMed ID: 5067202 [No Abstract] [Full Text] [Related]
13. Controlled clinical trial of 4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA 2370) and oxyphenbutazone in thrombophlebitis. Seghezzi R; Borri P; Chierichetti S; Ferrari P Arzneimittelforschung; 1972 Jan; 22(1):Suppl 1a:272-4. PubMed ID: 4553236 [No Abstract] [Full Text] [Related]
14. Clinical and pharmacokinetic studies of 4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA 2370) in obstetrics and gynaecology. Pecorari D; Ragni N; Chierichetti S Arzneimittelforschung; 1972 Jan; 22(1):Suppl 1a:278-8. PubMed ID: 5067205 [No Abstract] [Full Text] [Related]
15. Biochemical investigations of 4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA 2370). 2. Action on local and systemic chemical responses in the rat with an experimental inflammatory process. Coppi G; Bonardi G Arzneimittelforschung; 1972 Jan; 22(1):Suppl 1a:237+. PubMed ID: 5067200 [No Abstract] [Full Text] [Related]
16. Pharmacological investigations of 4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA 2370). 2. Ulcerogenic effects in rats and dogs. Marazzi-Uberti E; Bianchi C; Gaetani M; Pozzi L Arzneimittelforschung; 1972 Jan; 22(1):Suppl 1a:191-6. PubMed ID: 5067472 [No Abstract] [Full Text] [Related]
17. Pharmacological investigations of 4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA 2370). 3. General pharmacological properties. Bianchi C; Bonardi G Arzneimittelforschung; 1972 Jan; 22(1):Suppl 1a:196+. PubMed ID: 5067191 [No Abstract] [Full Text] [Related]
18. Clinical and laboratory studies of 4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA 2370) in bronchopulmonary diseases. Fumagalli G; Mazzola C; Chierichetti S Arzneimittelforschung; 1972 Jan; 22(1):Suppl 1a:274-8. PubMed ID: 5067204 [No Abstract] [Full Text] [Related]
19. Biochemical investigations of 4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA 2370). 1. Serum levels and urinary excretion in rats, rabbits and dogs. Coppi G; Bonardi G; Perego R Arzneimittelforschung; 1972 Jan; 22(1):Suppl 1a:234-6. PubMed ID: 5067199 [No Abstract] [Full Text] [Related]
20. Biochemical investigations of 4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA 2370). 4. Effects on erythrocyte membrane lysis and on red cells aggregation. Coppi G; Bonardi G Arzneimittelforschung; 1972 Jan; 22(1):Suppl 1a:247-9. PubMed ID: 5067201 [No Abstract] [Full Text] [Related] [Next] [New Search]